Holding CoVID in check through JAK? The MPN-approved compound ruxolitinib as a potential strategy to treat SARS-CoV-2 induced systemic hyperinflammation.

ABSTRACT:

SUBMITTER: Heidel F 

PROVIDER: S-EPMC7288260 | biostudies-literature | 2020 Jul

REPOSITORIES: biostudies-literature